

Recombinant																																														ME Variant	MM Variant	MU Variant	VI Variant	VG Variant	Total HQC(Q)																																																																																																																																																																																																																																																																																																																																																																											
XAR	XAH	XAB	XAG	XAM	XAW	XBB	XBL.1	XBL.11	XBL.12	XBL.13	XBL.14	XBL.15	XBL.16	XBL.17	XBL.18	XBL.19	XBL.20	XBL.21	XBL.22	XBL.23	XBL.24	XBL.25	XBL.26	XBL.27	XBL.28	XBL.29	XBL.30	XBL.31	XBL.32	XBL.33	XBL.34	XBL.35	XBL.36	XBL.37	XBL.38	XBL.39	XBL.40	XBL.41	XBL.42	XBL.43	XBL.44	XBL.45	XBL.46	XBL.47	XBL.48	XBL.49	XBL.50	XBL.51	XBL.52	XBL.53	XBL.54	XBL.55	XBL.56	XBL.57	XBL.58	XBL.59	XBL.60	XBL.61	XBL.62	XBL.63	XBL.64	XBL.65	XBL.66	XBL.67	XBL.68	XBL.69	XBL.70	XBL.71	XBL.72	XBL.73	XBL.74	XBL.75	XBL.76	XBL.77	XBL.78	XBL.79	XBL.80	XBL.81	XBL.82	XBL.83	XBL.84	XBL.85	XBL.86	XBL.87	XBL.88	XBL.89	XBL.90	XBL.91	XBL.92	XBL.93	XBL.94	XBL.95	XBL.96	XBL.97	XBL.98	XBL.99	XBL.100	XBL.101	XBL.102	XBL.103	XBL.104	XBL.105	XBL.106	XBL.107	XBL.108	XBL.109	XBL.110	XBL.111	XBL.112	XBL.113	XBL.114	XBL.115	XBL.116	XBL.117	XBL.118	XBL.119	XBL.120	XBL.121	XBL.122	XBL.123	XBL.124	XBL.125	XBL.126	XBL.127	XBL.128	XBL.129	XBL.130	XBL.131	XBL.132	XBL.133	XBL.134	XBL.135	XBL.136	XBL.137	XBL.138	XBL.139	XBL.140	XBL.141	XBL.142	XBL.143	XBL.144	XBL.145	XBL.146	XBL.147	XBL.148	XBL.149	XBL.150	XBL.151	XBL.152	XBL.153	XBL.154	XBL.155	XBL.156	XBL.157	XBL.158	XBL.159	XBL.160	XBL.161	XBL.162	XBL.163	XBL.164	XBL.165	XBL.166	XBL.167	XBL.168	XBL.169	XBL.170	XBL.171	XBL.172	XBL.173	XBL.174	XBL.175	XBL.176	XBL.177	XBL.178	XBL.179	XBL.180	XBL.181	XBL.182	XBL.183	XBL.184	XBL.185	XBL.186	XBL.187	XBL.188	XBL.189	XBL.190	XBL.191	XBL.192	XBL.193	XBL.194	XBL.195	XBL.196	XBL.197	XBL.198	XBL.199	XBL.200	XBL.201	XBL.202	XBL.203	XBL.204	XBL.205	XBL.206	XBL.207	XBL.208	XBL.209	XBL.210	XBL.211	XBL.212	XBL.213	XBL.214	XBL.215	XBL.216	XBL.217	XBL.218	XBL.219	XBL.220	XBL.221	XBL.222	XBL.223	XBL.224	XBL.225	XBL.226	XBL.227	XBL.228	XBL.229	XBL.230	XBL.231	XBL.232	XBL.233	XBL.234	XBL.235	XBL.236	XBL.237	XBL.238	XBL.239	XBL.240	XBL.241	XBL.242	XBL.243	XBL.244	XBL.245	XBL.246	XBL.247	XBL.248	XBL.249	XBL.250	XBL.251	XBL.252	XBL.253	XBL.254	XBL.255	XBL.256	XBL.257	XBL.258	XBL.259	XBL.260	XBL.261	XBL.262	XBL.263	XBL.264	XBL.265	XBL.266	XBL.267	XBL.268	XBL.269	XBL.270	XBL.271	XBL.272	XBL.273	XBL.274	XBL.275	XBL.276	XBL.277	XBL.278	XBL.279	XBL.280	XBL.281	XBL.282	XBL.283	XBL.284	XBL.285	XBL.286	XBL.287	XBL.288	XBL.289	XBL.290	XBL.291	XBL.292	XBL.293	XBL.294	XBL.295	XBL.296	XBL.297	XBL.298	XBL.299	XBL.300	XBL.301	XBL.302	XBL.303	XBL.304	XBL.305	XBL.306	XBL.307	XBL.308	XBL.309	XBL.310	XBL.311	XBL.312	XBL.313	XBL.314	XBL.315	XBL.316	XBL.317	XBL.318	XBL.319	XBL.320	XBL.321	XBL.322	XBL.323	XBL.324	XBL.325	XBL.326	XBL.327	XBL.328	XBL.329	XBL.330	XBL.331	XBL.332	XBL.333	XBL.334	XBL.335	XBL.336	XBL.337	XBL.338	XBL.339	XBL.340	XBL.341	XBL.342	XBL.343	XBL.344	XBL.345	XBL.346	XBL.347	XBL.348	XBL.349	XBL.350	XBL.351	XBL.352	XBL.353	XBL.354	XBL.355	XBL.356	XBL.357	XBL.358	XBL.359	XBL.360	XBL.361	XBL.362	XBL.363	XBL.364	XBL.365	XBL.366	XBL.367	XBL.368	XBL.369	XBL.370	XBL.371	XBL.372	XBL.373	XBL.374	XBL.375	XBL.376	XBL.377	XBL.378	XBL.379	XBL.380	XBL.381	XBL.382	XBL.383	XBL.384	XBL.385	XBL.386	XBL.387	XBL.388	XBL.389	XBL.390	XBL.391	XBL.392	XBL.393	XBL.394	XBL.395	XBL.396	XBL.397	XBL.398	XBL.399	XBL.400	XBL.401	XBL.402	XBL.403	XBL.404	XBL.405	XBL.406	XBL.407	XBL.408	XBL.409	XBL.410	XBL.411	XBL.412	XBL.413	XBL.414	XBL.415	XBL.416	XBL.417

INSACOG BULLETIN

Global Scenario

Globally, nearly 2.7 million new cases and 17000 deaths have been reported in the last 28 days^[1]. During the week 18 of the year 2023, there has been a continued decreasing trend in the proportions of recombinant lineages globally. However, the picture is mixed at the regional level, with increases in reported cases seen in the South-East Asia and Western Pacific regions and decreases in other regions. Currently, there are two variants of interest (VOI), XBB.1.5 & XBB.1.16 and six variants under monitoring (VUMs). The VUMs are BA.2.75, CH.1.1, BQ.1, XBB, XBB.1.9.1, and XBB.1.9.2. The variant XBF has been removed from the list of VUMs due to its declining prevalence. Globally, XBB.1.5 has been detected in 109 countries and continues to be the most prevalent variant, accounting for 47.5% of cases in epidemiological week 18. XBB.1.16 has been reported from 46 countries and accounted for 8.6% of sequences submitted till date. However, rise in hospitalizations, ICU admissions, or deaths due to the circulating XBB variants have not been reported.


Indian Scenario

Omicron and its sub-lineages continue to be the dominant variants in India. The prevalence of recombinant variant XBB.1.16 has increased in different parts of India compared to last week, accounting for 87.1% of the infection till date. Among the samples collected till the second week of May 2023, other XBB sub-lineages accounted for 12.9% of the current infection. The number of samples were relatively low in some part of India. No increase in disease severity or hospitalization has been reported.

Country wide analysis:

Week wise lineage distribution

As on: 12/05/2023 10:29:05




INSACOG BULLETIN

Region-wise analysis:


North India - Week wise lineage distribution

As on: 12/05/2023 10:29:05



East India - Week wise lineage distribution


As on: 12/05/2023 10:29:05



INSACOG BULLETIN


NorthEast India - Week wise lineage distribution

As on: 12/05/2023 10:29:05



West India - Week wise lineage distribution


As on: 12/05/2023 10:29:05



INSACOG BULLETIN


South India - Week wise lineage distribution

As on: 12/05/2023 10:29:05



Central India - Week wise lineage distribution

As on: 12/05/2023 10:29:05



Reference:

1. WHO weekly epidemiological report.